Josep M. Tabernero

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 585 publications

Relative Mutant Allele Frequency Role in ctDNA-Guided Anti-Epidermal Growth Factor Receptor Rechallenge in Metastatic Colorectal Cancer.

Relative Mutant Allele Frequency Role in ctDNA-Guided Anti-Epidermal Growth Factor Receptor Rechallenge in Metastatic Colorectal Cancer.

Journal: JCO precision oncology

Published: September 01, 2026

Rechallenge With Anti-Human Epidermal Growth Factor Receptor 2 Therapy Guided by Liquid Biopsy in HER2-Amplified Metastatic Colorectal Cancer.

Rechallenge With Anti-Human Epidermal Growth Factor Receptor 2 Therapy Guided by Liquid Biopsy in HER2-Amplified Metastatic Colorectal Cancer.

Journal: JCO precision oncology

Published: July 29, 2026

Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.

Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.

Journal: The New England journal of medicine

Published: May 27, 2026

Quality and safety of research biopsies in oncology clinical trials.

Quality and safety of research biopsies in oncology clinical trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 21, 2026

Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer Patients.

Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer Patients.

Journal: Genes

Published: March 10, 2026

Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients.

Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations.

Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial.

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Biomarker-guided immunotherapy in gastric cancer: current insights and future perspectives.

Biomarker-guided immunotherapy in gastric cancer: current insights and future perspectives.

Journal: Cancer treatment reviews

Published: February 06, 2026

Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain: results from the global FRESCO-2 study.

Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain: results from the global FRESCO-2 study.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Intratumoral Fusobacterium species and survival in resectable colorectal cancer: a multicenter cohort study.

Intratumoral Fusobacterium species and survival in resectable colorectal cancer: a multicenter cohort study.

Journal: ESMO open

Published: January 30, 2026

Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumors.

Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 27, 2026

Showing 1-12 of 585

Last Updated: 09/26/2026